Home › NDC Lookup › RxCUI directory › RxCUI 105551

Busulfan 2 MG Oral Tablet [Myleran] — RxCUI 105551

RxNorm drug concept · Semantic branded drug
RxCUI 105551 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI105551
Official nameBusulfan 2 MG Oral Tablet [Myleran]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asMyleran 2 MG Oral Tablet
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Busulfan Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • BUSULFEX is a chemotherapy drug used to prepare your body for a stem cell transplant when you have chronic myelogenous leukemia, a type of blood cancer. It's given alongside anothe...
  • BUSULFEX is given through a central IV line — a catheter placed in a large vein — as a slow infusion over two hours. You'll receive a dose every six hours for four days in a row, f...
  • How is BUSULFEX given, and how long does the treatment take?
  • Almost everyone experiences nausea, vomiting, mouth sores, diarrhea, fever, and significant fatigue — these are expected and your care team will help manage them. The more serious...
📖 Read our full Busulfan Injection guide →

🕸️ Concept Web — How Busulfan 2 MG Oral Tablet [Myleran] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Busulfan 2 MG Oral Tablet [Myleran] RxCUI 105551

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Busulfan 1828
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Myleran 203010
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Busulfan Oral Tablet 371165
    • Busulfan Oral Product 1151375
    • Busulfan Pill 1151376
    • Busulfan Oral Tablet [Myleran] 368542
    • Myleran Oral Product 1185666
    • Myleran Pill 1185667
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Busulfan 2 MG Oral Tablet SCD · 197422
  • Busulfan 2 MG SCDC · 317620
  • Busulfan Oral Tablet SCDF · 371165
  • Busulfan Oral Product SCDG · 1151375
  • Busulfan Pill SCDG · 1151376

Brand-Name Concepts

  • Busulfan 2 MG [Myleran] SBDC · 564078
  • Busulfan Oral Tablet [Myleran] SBDF · 368542
  • Myleran Oral Product SBDG · 1185666
  • Myleran Pill SBDG · 1185667
  • Myleran BN · 203010

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 105551 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
80725-0620-25 25 TABLET, FILM COATED in 1 BOTTLE (80725-620-25) MYLERAN Waylis Therapeutics LLC 2023-05-15
Observed labelers: Waylis Therapeutics LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.